Protective LRRK2 R1398H Variant Enhances GTPase and Wnt Signaling Activity
Jonathon Nixon‐Abell(National Institutes of Health), Kirsten Harvey(University College London)
Cited by 69
Related Papers
Pathogenic LRRK2 variants are gain-of-function mutations that enhance LRRK2-mediated repression of β-catenin signaling
|Molecular Neurodegeneration|2017|52
Dysregulated Wnt and NFAT signaling in a Parkinson’s disease LRRK2 G2019S knock-in model
|Scientific Reports|2024|17